Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL311322 | 0.74 | TSHR (0.50) | ALDH1A1TSHRMAPK1TP53CYP3A4 | |
| SCHEMBL6430798 | 0.74 | ALDH1A1 (0.54) | ALDH1A1TSHRMAPK1TP53CYP3A4 | |
| SCHEMBL594507 | 0.71 | TSHR (0.57) | ALDH1A1TSHRMAPK1TP53CYP3A4 | |
| SCHEMBL1192277 | 0.71 | ALDH1A1 (0.61) | ALDH1A1TSHRMAPK1TP53CYP3A4 | |
| SCHEMBL1537333 | 0.71 | TSHR (0.57) | ALDH1A1TSHRMAPK1TP53CYP3A4 | |
| SCHEMBL311323 | 0.71 | TSHR (0.57) | ALDH1A1TSHRMAPK1TP53CYP3A4 | |
| SCHEMBL12677361 | 0.71 | TSHR (0.57) | ALDH1A1TSHRMAPK1TP53CYP3A4 | |
| SCHEMBL7170116 | 0.70 | ALDH1A1 (0.60) | ALDH1A1TSHRMAPK1TP53CYP3A4 | |
| SCHEMBL1004395 | 0.69 | TSHR (0.55) | ALDH1A1TSHRMAPK1TP53CYP3A4 | |
| SCHEMBL16296603 | 0.69 | TSHR (0.50) | ALDH1A1TSHRMAPK1TP53CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180077899-A1 | Methods and Compositions for Dag Mitigation | INVENTION DEVELOPMENT MANAGEMENT COMPANY, LLC | 2018-03-22 | — | — | US | claimed |
| WO-2018057323-A1 | METHODS AND COMPOSITIONS FOR DAG MITIGATION | EMPIRE TECHNOLOGY DEVELOPMENT LLC (US) | 2018-03-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180077899-A1 | Methods and Compositions for Dag Mitigation | DAGLB, DAGLA, DGAT2 | ALDH1A1 1193/4885TSHR 4511/4885MAPK1 4226/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.